News and Events

The updated ICHQ5A(R2) guideline adopted in November 2023 highlights the benefits of Next Generation Sequencing assays versus in vivo assays: 3.2.3: "NGS is encouraged as a replacement for in vivo assays because it can overcome the limitations of the breadth and...

Listen to an archived version of our recent webinar which provided information on our new integration site analysis assay. The assay uses Cas9 targeted DNA cleavage combined with nanopore sequencing technology to comprehensively sequence the junction site. This assay...

Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French AgencyPathoQuest is pleased to announce that the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) have recently published their review of PathoQuest’s...

PathoQuest now offering GMP validated NGS Viral Vector Identity test at U.S. siteWe now offer our GMP validated Viral Vector Identity test at our Wayne, PA site, as well as at our site in Paris, France. Our NGS-based identity test is performed on a short read...

PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD contributes featured blog post on the ICH Q5A(R2) on Eureka science blogA new post on Charles River’s Eureka science blog feature’s PathoQuest’s Chief Pharmaceutical Officer, Sébastien Renouf, PharmD,...

Jean-Francois Brepson interviewed for Amazon Web Services (AWS) Health Innovation Podcast Discover how PathoQuest enables new biotherapies to be delivered rapidly and safely to patients with its quality testing platform in this episode of the AWS Health Innovation...

Video Blog – SENSITIVITY, SCALABILITY AND SPEED: The Value of Next Generation Sequencing (NGS) for Identity Testing of Plasmids & Viral VectorsIdentity testing is critical for ensuring quality and safety of biopharmaceuticals. As such, identity testing is a key...

PathoQuest Reiterates its Strategic Growth Plans by Appointing Daniel Spasic to the BoardDaniel Spasic, a highly experienced lifescience business leader, has been appointed as a non-executive director to the board of PathoQuest.  With over 25 years of hands-on...

PathoQuest Announce the Opening of its New U.S. Facility The Leading Experts in NGS Biosafety Testing and Characterization of Biopharmaceuticals Launch New Capabilities in the Critical U.S. Market Wayne, PA, and Paris, France – October 4, 2022 – PathoQuest, a leader...

A Podcast from Transgene: NGS-Based Biosafety Strategy for Breakthrough Virus-Based Immunotherapies Transgene is a French biotech developing virus-based immunotherapies. There manufacturing processes deal with breakthrough therapeutic vaccines highly awaited by...

PathoQuest Appoints Rainer Metzger, Ph.D. as Chairman of the Board of DirectorsPARIS, FRANCE – September 1st, 2022 – PathoQuest, a pioneer of next-generation sequencing (NGS)-based testing solutions for the quality control of biologics, today announced the appointment...

PathoQuest Announces Appointment of Michael Mellor-Clark as Chief Commercial Officer PARIS, FRANCE, June 23, 2022 – PathoQuest, a leading Contract Research Organization (CRO) for the biosafety testing of biologics with Next-Generation Sequencing (NGS) technologies,...

PathoQuest Appoints Sébastien Renouf, Pharm D., as Chief Pharmaceutical Officer Dr. Sébastien Renouf has almost 20 years of experience in Regulatory Affairs, Risk Management, Quality Assurance, and Safety Control for Cell & Gene Therapy.  Before joining...